The American Journal of Managed Care

Most Patients With MCL in Study of Pirtobrutinib Show Stable or Improved Physical Symptoms, QOL

Among patients with MCL still on study in January 2025, 35.3% reported improved MCL-related symptoms, while 5.9% reported ...

Jaypirca® (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, Now Available in Canada for Adult Patients with Relapsed or Refractory Mantle Cell ...

Eli Lilly Canada, Inc announced today that Jaypirca® (pirtobrutinib, 100 mg & 50 mg tablets) is now approved and available ...
Cure Today

Treatment Discontinuations Reduced With Jaypirca in CLL, SLL

Jaypirca showed superior PFS and lower discontinuation rates compared to standard treatments in CLL/SLL patients. Jaypirca reduced the risk of progression or death by 46% to 52% and had a favorable ...
Healio

VIDEO: Pirtobrutinib makes inroads in CLL, SLL as potential first-line therapy

Please provide your email address to receive an email when new articles are posted on . ORLANDO — In this video, Matthew S. Davids, MD, said data from the BRUIN-313 trial supports front-line approval ...
Monthly Prescribing Reference

Jaypirca Gains CLL/SLL Indication Through Accelerated Approval Pathway

The accelerated approval was based on data from the phase 1/2 BRUIN trial that included a subset of 108 patients with CLL/SLL. The Food and Drug Administration (FDA) has granted accelerated approval ...
The American Journal of Managed Care

CLL Breakthrough: 100% Efficacy Reported for VenR Retreatment

Retreatment with venetoclax and rituximab in CLL patients achieved 100% response rates and prolonged progression-free ...
Nasdaq

U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or ...

Breyanzi offers a personalized treatment option delivered as a one-time infusion that provides deep and durable responses for patients with relapsed or refractory CLL or SLL who have historically had ...
Monthly Prescribing Reference

FDA Expands Jaypirca Indication for Relapsed/Refractory CLL/SLL

At a median duration of follow-up of 6.6 months, treatment with pirtobrutinib reduced the risk of progression or death by 42%. The Food and Drug Administration (FDA) has approved Jaypirca ® ...
Healio

VIDEO: Pirtobrutinib ‘on the map’ as first-line, second-line CLL, SLL option

Please provide your email address to receive an email when new articles are posted on . In the BRUIN CLL-313 trial, researchers compared pirtobrutinib (Jaypirca, Eli Lilly & Co.) vs. bendamustine plus ...
Medscape

FDA Approves First CAR T-Cell Therapy for rrCLL, rrSLL

The US Food and Drug Administration (FDA) has granted accelerated approval for lisocabtagene maraleucel (liso-cel) for the treatment of certain adults with relapsed or refractory chronic lymphocytic ...
WebMD

Treating Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With Copiktra

Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...
Cure Today

Breyzani Benefits Previously Treated SLL, CLL

CAR T-cell therapy positively benefitted patients with patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Breyanzi (lisocabtagene maraleucel), ...